Moreover, since BRAFV600E mutation was demonstrated to be associated with an increased expression of AhR, particularly at the infiltrative tumour edge, in thyroid cancer murine models [17], and the associations between the molecules here investigated and other mutations implied in thyroid cancer pathogenesis, progression and prognosis (e.g., RET/PTC, TP53, TERT, ATK1 and RAS) have not yet been described [40], additional studies at the molecular level of these aspects should be conducted. This evidence concerns the gene TP53 and thyroid cancer.